Risk factors for a non-favorable outcome after treated European neuroborreliosis

• Published in: Acta neurologica Scandinavica Vol. 127; no. 3; pp. 154 - 160
• Main Authors: Eikeland, R., Mygland, Å., Herlofson, K., Ljøstad, U.
• Format: Journal Article
• Language: English
• Published: Denmark Blackwell Publishing Ltd 01.03.2013; Hindawi Limited
• Subjects: Age; Anti-Bacterial Agents - therapeutic use; Borrelia; Borreliosis; Ceftriaxone - therapeutic use; Central nervous system; Cerebrospinal fluid; Composite materials; Demography; Doxycycline - therapeutic use; Europe; Fatigue; Fatigue - epidemiology; Fatigue - etiology; Female; Gender; Humans; inflammation; Inventories; Laboratory testing; Lyme disease; Lyme neuroborreliosis; Lyme Neuroborreliosis - complications; Lyme Neuroborreliosis - drug therapy; Male; Middle Aged; predictors; Quality of Life; Risk Factors; Surveys and Questionnaires; Treatment Outcome; Europe
• ISSN: 0001-6314; 1600-0404
• DOI: 10.1111/j.1600-0404.2012.01690.x

Aim To identify possible risk factors for reduced health‐related quality of life (HRQoL) and fatigue after treated Lyme neuroborreliosis (LNB). Methods We included 50 patients with LNB and analyzed associations between their demographic, clinical, and laboratory characteristics at baseline and outcome at 30 months assessed by the self‐report questionnaires Short Form‐36 (SF‐36) and Fatigue Severity Scale (FSS). Results Lower scores in the SF‐36 domain Physical Component Summary were associated with pretreatment symptom duration >6 weeks (B = −11.0, P = 0.001) and non‐complete recovery at 4 months (B = −5.5, P = 0.037) (R2 = 0.35). Lower scores in the SF‐36 domain Mental Component Summary were associated with non‐complete recovery at 4 months (B = −8.9, P = 0.01 (R2 = 0.14). Higher FSS scores were associated with pretreatment symptom duration >6 weeks (B = 1.4, P = 0.006), high scores on the composite clinical score pretreatment (B = 0.1, P = 0.003), and non‐complete recovery at 4 months (B = 1.6, P = 0.005) (R2 = 0.46). No laboratory test results were associated with these predefined outcomes. Conclusions Delayed treatment start, more symptoms and findings before treatment, and non‐complete recovery at 4 months after treatment are possible predictors of a poorer HRQoL and more fatigue 30 months after treated LNB. We did not find age, gender, educational level, involvement of the central nervous system, coexisting diseases, or cerebrospinal fluid findings to be associated with reduced HRQoL or fatigue. Our findings should be replicated in future studies before any conclusions can be drawn.